Singular Genomics Ownership
| OMIC Stock | USD 21.37 0.05 0.23% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Singular |
Singular Stock Ownership Analysis
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Singular Genomics Systems recorded a loss per share of 34.68. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 26th of June 2024. Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California. Singular Genomics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 248 people. To find out more about Singular Genomics Systems contact Andrew Spaventa at 858 333 7830 or learn more at https://www.singulargenomics.com.Besides selling stocks to institutional investors, Singular Genomics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Singular Genomics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Singular Genomics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Singular Genomics Quarterly Liabilities And Stockholders Equity |
|
Singular Genomics Insider Trades History
About 14.0% of Singular Genomics Systems are currently held by insiders. Unlike Singular Genomics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Singular Genomics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Singular Genomics' insider trades
Singular Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Singular Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Singular Genomics Systems backward and forwards among themselves. Singular Genomics' institutional investor refers to the entity that pools money to purchase Singular Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hightower Advisors, Llc | 2024-06-30 | 17.6 K | Tikvah Management Llc | 2024-06-30 | 10.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726 | Tower Research Capital Llc | 2024-06-30 | 528 | Barclays Plc | 2024-06-30 | 409 | Bank Of America Corp | 2024-06-30 | 367 | Royal Bank Of Canada | 2024-06-30 | 87.0 | Rhumbline Advisers | 2024-06-30 | 55.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 36.0 | Tang Capital Management Llc | 2024-09-30 | 372 K | Deerfield Management Co | 2024-09-30 | 166.2 K |
Singular Genomics Systems Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Singular Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Singular Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Singular Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Singular Genomics Outstanding Bonds
Singular Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Singular Genomics Systems uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Singular bonds can be classified according to their maturity, which is the date when Singular Genomics Systems has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Singular Genomics Corporate Filings
F3 | 22nd of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 5th of November 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.